查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2018693

核酸增幅检查市场：依技术、产品类型、最终用户和应用划分－2026-2032年全球市场预测

Nucleic Acid Amplification Testing Market by Technology, Product Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，核酸增幅检查市场价值将达到 40 亿美元，到 2026 年将成长至 45.4 亿美元，年复合成长率为 13.20%，到 2032 年将达到 95.4 亿美元。

主要市场统计数据
基准年 2025 40亿美元
预计年份：2026年 45.4亿美元
预测年份 2032 95.4亿美元
复合年增长率 (%) 13.20%

为核酸增幅检查，这对于临床医学和公共卫生领域的诊断和调查至关重要。

核酸增幅检查(NAAT) 曾经是检查室的专业技术，但如今已成为现代诊断、研究和临床决策的基石。分子生物学、仪器和软体的进步拓展了扩增检测的应用范围和方法，使得在临床、公共卫生和研究领域能够更快、更准确地检测遗传物质。本文概述了塑造当前局面的技术基础、市场驱动因素和营运背景，并重点探讨了创新与推广应用障碍之间的相互作用。

重构核酸增幅检查，并确定影响其应用和商业化的关键技术和操作转折点。

核酸增幅检查的现状正经历着一场变革，其驱动力包括技术融合、检测分散化以及人们对快速、可操作结果日益增长的需求。这种融合在先进化学技术数位资料分析的整合中尤其明显，数位PCR平台和即时PCR仪如今与成熟的等温PCR方法并存，简化了工作流程。虽然这种变化使得核酸扩增检测能够在非常规环境中得到更广泛的应用，但也带来了新的性能权衡和监管方面的考虑。

我们评估了近期关税趋势如何对整个 NAAT 价值链的采购、在地化生产、定价策略和创新时间表施加多方面的压力。

2025年实施的新关税措施和贸易政策变化迫使核酸增幅检查系统中的相关人员在其采购、定价和供应连续性策略中全面考虑这些因素。仪器、试剂和配件的关税可能会推高接收成本，并挤压经销商和服务供应商的利润空间，促使许多买家重新评估其供应商组合和库存策略。为此，一些製造商和检测实验室正在转向双重采购、确保替代供应管道并建立缓衝库存，以降低短期供应中断的风险。

我们提供有关技术、产品、最终用户和应用的详细见解，阐明效能权衡和商业化途径。

核酸增幅检查策略规划的核心在于技术选择，目前市场对等温扩增及聚合酵素链锁反应(PCR) 平台均有广泛的探讨。等温扩增方法包括多种变体，例如解旋酶依赖性扩增、环介导扩增、核酸序列扩增、链置换扩增和转录媒介增幅，每种方法在速度、仪器简易性和温度控制方面都各具优势。相较之下，聚合酵素链锁反应(PCR) 技术则根据其模式进行区分：数位 PCR 和即时PCR 。数位平台强调绝对定量和灵敏度，而即时系统则专注于临床工作流程中的通量和动态数据。

本文说明了区域法规结构、投资趋势和製造能力如何在全球主要地区形成不同的采用路径。

区域趋势正在影响美洲、欧洲、中东和非洲以及亚太地区的投资重点、监管方式和经营模式，每个地区都呈现出独特的机会和营运考量。在美洲，由于医疗网路一体化和报销机製成熟，对高通量检测系统和照护现场能力的需求持续旺盛。同时，监管路径强调对临床效用的严格检验和论证。该地区在应对疫情和基因组监测方面也获得了大量的公共和私人投资，从而推动了各种核酸扩增检测（NAAT）技术的广泛应用。

我们将检验策略经营模式、伙伴关係生态系统和营运投资，这些模式和投资使公司能够在设备、试剂和资讯服务。

核酸增幅检查领域的企业策略体现了技术创新、营运韧性和商业性规模之间的平衡。主要企业正投资于整合型产品组合，将强大的仪器平台与专有试剂和数据分析能力相结合，以确保可持续的收入来源和竞争优势。同时，一些企业正专注于模组化或开放平台方案，利用第三方试剂和检测开发合作伙伴，加速在不同终端用户环境中的部署。

为了推动永续成长，我们制定了技术发展、供应链多元化、监管合作和服务主导商业化的高优先级策略行动。

产业领导企业应采取多管齐下的策略，使其技术蓝图与供应链韧性和以客户为中心的商业化相契合。优先开发模组化平台，以支援集中式高吞吐量需求和分散式照护现场部署，从而使单一产品系列能够利用通用耗材和检验的工作流程满足多种终端用户需求。这种方法可以降低客户的复杂性，并加速在所有环境中的部署。

概述一项混合方法研究，该研究结合了专家访谈、技术审查和情境分析，以检验核酸增幅检查。

本分析的调查方法结合了结构化的初步调查、有针对性的二次调查以及严格的检验，以确保其相关性和准确性。初步调查包括对临床实验室主任、医院采购负责人、检测开发人员和技术供应商的详细访谈，以收集有关推广应用驱动因素、营运障碍和采购趋势的实际见解。此外，还与分子生物学家和生物资讯学专家进行了技术咨询，以评估检测性能方面的权衡取舍和整合挑战，从而补充了这些定性资讯。

本报告总结了技术进步、营运韧性和政策因素的融合，这些因素共同塑造了核酸增幅检查的长期应用和价值创造。

总之，核酸增幅检查正处于一个策略转折点，技术创新、商业策略和政策动态在此交汇，共同塑造其未来发展方向。等温和先进PCR技术的成熟、携带式和台式平台的普及以及复杂数据分析工具的集成，正在拓展其应用范围和应用环境。同时，贸易政策、监管预期和区域製造地的变化，要求相关人员在采购、检验和市场准入方面做出谨慎的决策。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：核酸增幅检查市场：依技术划分

  • 等温扩增
    • 解旋酶依赖性扩增
    • 环介导扩增
    • 基于核酸序列的扩增
    • 链取代扩增
    • 转录媒介增幅
  • 聚合酵素链锁反应
    • 数位聚合酵素链锁反应
    • 即时聚合酵素链锁反应

第九章：核酸增幅检查市场：依产品类型划分

  • 装置
    • 桌面设备
    • 可携式设备
  • 试剂和试剂盒
    • 缓衝溶液
    • 酵素
    • 母带混音
    • 引子和探针
  • 软体服务
    • 数据分析软体
    • 维护和支援
    • 培训和咨询服务

第十章：核酸增幅检查市场：依最终用户划分

  • 诊断检查室
  • 医院
  • 即时检测
  • 研究机构

第十一章：核酸增幅检查市场：依应用领域划分

  • 伴随诊断
  • 基因检测
    • 携带者筛检
    • 产前基因检测
    • 罕见疾病的诊断
  • 感染疾病
    • 细菌感染疾病
    • 寄生虫感染疾病
    • 性行为感染
  • 肿瘤学
    • 生物标记检测
    • 微量残存疾病的检测
    • 突变分析

第十二章：核酸增幅检查市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：核酸增幅检查市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：核酸增幅检查市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国核酸增幅检查市场

第十六章：中国核酸增幅检查市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bruker Corporation
  • Danaher Corporation
  • Diasorin SpA
  • F. Hoffmann-La Roche AG
  • Grifols, SA
  • Hologic, Inc.
  • Molbio Diagnostics Pvt. Ltd.
  • Mylab Discovery Solutions
  • Pfizer Inc
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AD36CD897FB8

The Nucleic Acid Amplification Testing Market was valued at USD 4.00 billion in 2025 and is projected to grow to USD 4.54 billion in 2026, with a CAGR of 13.20%, reaching USD 9.54 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.00 billion
Estimated Year [2026] USD 4.54 billion
Forecast Year [2032] USD 9.54 billion
CAGR (%) 13.20%

Establishing the foundational context for nucleic acid amplification testing as an essential diagnostic and research enabler across clinical and public health environments

Nucleic acid amplification testing (NAAT) has evolved from a laboratory specialty into a cornerstone of modern diagnostics, research, and point-of-care decision-making. Advances in molecular biology, instrumentation, and software have expanded where and how amplification assays are deployed, enabling faster, more accurate detection of genetic material across clinical, public health and research settings. This introduction frames the technological foundations, market drivers, and operational contexts that shape the current landscape while highlighting the interplay between innovation and adoption barriers.

Rapid polymerase chain reaction (PCR) workflows and diversified isothermal approaches have broadened assay capability beyond centralized laboratories, empowering clinicians with actionable data at the bedside and supporting large-scale surveillance programs. At the same time, reagent chemistry optimization, miniaturized benchtop and portable instruments, and improvements in data analysis pipelines have driven throughput gains and permitted more complex multiplexing strategies. These developments are accompanied by evolving regulatory expectations and quality requirements that determine how assays transition from development to routine use.

Taken together, NAAT is positioned at the nexus of clinical need, regulatory rigor and technological possibility. Understanding the current state requires evaluating the full value chain from assay chemistry and instrument design through to software and service delivery, and this report's introduction grounds subsequent analyses in those practical realities.

Identifying the major technological and operational inflection points reshaping nucleic acid amplification testing with implications for adoption and commercialization

The landscape of nucleic acid amplification testing is undergoing transformative shifts driven by technology convergence, decentralization of testing, and heightened expectations for rapid, actionable results. Convergence is evident in the integration of advanced chemistry with digital data analysis, where digital PCR platforms and real-time PCR instruments now coexist alongside a maturing suite of isothermal methods that facilitate simplified workflows. This shift enables broader adoption in non-traditional settings while also introducing new performance trade-offs and regulatory considerations.

Decentralization has accelerated as portable and benchtop instruments become more reliable and user-friendly, enabling point-of-care applications in emergency medicine, outpatient clinics and field use for infectious disease surveillance. Simultaneously, reagent innovation-including master mixes, optimized enzymes and stabilized buffers-has reduced cold-chain dependencies and extended assay lifetimes, supporting mobile deployments. The rise of cloud-native data analysis and laboratory information management integrations is enhancing throughput and traceability, while also raising new data governance and cybersecurity requirements.

Finally, strategic shifts among stakeholders, including vertical integration by product manufacturers and increased collaboration between diagnostics developers and service providers, are reshaping go-to-market dynamics. These changes collectively redefine how tests are developed, validated and delivered, and they create both opportunities and new operational complexities for laboratories, health systems and commercial players.

Assessing how recent tariff developments exert multifaceted pressure on sourcing, manufacturing localization, pricing strategies and innovation timelines across the NAAT value chain

The imposition of new tariff measures and trade policy changes in 2025 has created a cumulative set of considerations that stakeholders in the nucleic acid amplification testing ecosystem must now factor into sourcing, pricing and supply continuity strategies. Tariffs that target instruments, reagents and ancillary components escalate landed costs and can compress margins for distributors and service providers, prompting many buyers to reassess supplier portfolios and inventory strategies. In response, some manufacturers and laboratories are moving toward dual-sourcing, qualifying alternative supply lines, and building buffered inventory to mitigate short-term disruption risk.

Beyond direct cost implications, tariffs influence longer-term strategic decisions such as localization of production, contractual rebalancing with tier-one suppliers, and increased scrutiny of value chain transparency. Firms that previously relied heavily on single-country manufacturing may accelerate plans to diversify production footprints or to enter co-manufacturing partnerships to preserve market access while controlling costs. Regulatory approvals and quality management systems add complexity to these moves, because relocating production requires sustained investment in compliance and validation.

Moreover, tariffs have knock-on effects on innovation timelines and capital allocation, as higher import costs can deter investment in new instrument lines or reagent chemistries that are capital-intensive. For organizations that operate across borders, harmonizing procurement policies and updating cost modeling to reflect tariff scenarios is essential. Adopting scenario-based financial planning and strengthening relationships with logistics and customs specialists will help stakeholders navigate the cumulative impacts of trade policy shifts in 2025 and beyond.

Delivering nuanced insights across technology, product, end user and application dimensions to clarify performance trade-offs and commercialization pathways

Technology choices are central to strategic planning in nucleic acid amplification testing, with the market broadly studied across isothermal amplification and polymerase chain reaction platforms. Isothermal methods encompass variants such as helicase dependent amplification, loop mediated amplification, nucleic acid sequence based amplification, strand displacement amplification and transcription mediated amplification, each offering distinct advantages in speed, equipment simplicity and temperature control. In contrast, polymerase chain reaction techniques are differentiated by digital PCR and real-time PCR modalities, with digital platforms emphasizing absolute quantification and sensitivity while real-time systems focus on throughput and kinetic data for clinical workflows.

Product type segmentation highlights that instrument platforms, reagents and kits, and software and services form mutually reinforcing pillars of capability. Instruments are available in benchtop and portable formats to suit laboratory and point-of-care environments respectively, while reagents and kits cover critical consumables such as buffers, enzymes, master mixes and primers and probes that underpin assay performance. Software and services-including data analysis software, maintenance and support, and training and consulting services-are increasingly integral to successful deployment and ongoing operational optimization.

End user differentiation spans diagnostic laboratories, hospitals, point of care testing sites and research institutes, with each segment exhibiting unique throughput, regulatory and staffing requirements that influence procurement decisions. Application-focused segmentation further clarifies clinical priorities, encompassing companion diagnostics, genetic testing, infectious disease and oncology. Within genetic testing, sub-specializations such as carrier screening, prenatal testing and rare disease diagnostics demand distinct assay sensitivity and reporting workflows, while infectious disease categories cover bacterial, parasitic and viral detection needs. Oncology applications concentrate on biomarker testing, minimal residual disease detection and mutation analysis, driving demand for high-sensitivity platforms and robust bioinformatics.

Explaining how regional regulatory frameworks, investment patterns and manufacturing capabilities create distinct adoption pathways across major global geographies

Regional dynamics shape investment priorities, regulatory approaches and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct opportunities and operational considerations. In the Americas, there is sustained demand for high-throughput laboratory systems and point-of-care capabilities driven by integrated healthcare networks and a mature reimbursement environment, while regulatory pathways emphasize rigorous validation and clinical utility demonstrations. This region also demonstrates strong private and public investment into pandemic preparedness and genomic surveillance initiatives, supporting broad uptake of diverse NAAT technologies.

The Europe, Middle East & Africa region presents a heterogeneous landscape: Western European markets often adopt advanced instrumentation and precision diagnostics, supported by structured regulatory frameworks and centralized laboratory networks, whereas emerging markets in the Middle East and Africa prioritize cost-effective, portable solutions and training to expand access. Cross-border regulatory harmonization and regional procurement programs can accelerate adoption but also require manufacturers to navigate varied compliance regimes and logistical challenges.

Asia-Pacific is characterized by rapid adoption of decentralized testing models, significant local manufacturing capacity and strong government-led initiatives to expand diagnostics infrastructure. Several markets in this region are investing heavily in domestic production, which can influence global supply chains and competitive dynamics. Across regions, differences in reimbursement, clinical practice, and public health priorities necessitate tailored market entry and commercialization strategies that align technology portfolios with local needs and regulatory expectations.

Examining strategic business models, partnership ecosystems and operational investments that position companies to capture value across instruments, reagents and data services

Company strategies in the nucleic acid amplification testing sphere reflect a balance between technological innovation, operational resilience and commercial scale. Leading organizations are investing in integrated portfolios that combine robust instrument platforms with proprietary reagents and data analytics capabilities to create recurring revenue streams and competitive differentiation. Simultaneously, some firms concentrate on modular or open-platform approaches that allow third-party reagents and assay development partners to accelerate adoption across diverse end-user settings.

Partnerships and collaborations are prevalent, spanning co-development with academic groups, licensing arrangements for assay chemistries, and strategic alliances with service providers to expand market reach. Business models that emphasize service contracts, training, and maintenance can deepen customer relationships and stabilize revenue over time. In parallel, firms are scaling manufacturing and supply chain processes, including investments in regional production capacity and quality systems to meet regulatory demands and to mitigate tariff exposure.

Organizational focus on data services and cloud-enabled software reflects recognition that actionable interpretation and workflow integration are as important as raw assay performance. Companies prioritizing regulatory expertise, customer support infrastructure and flexible commercialization options are better positioned to penetrate hospital systems, diagnostic laboratories and decentralized care settings, enabling sustained growth as testing paradigms evolve.

Providing prioritized strategic actions for technology development, supply chain diversification, regulatory engagement and service-led commercialization to drive sustainable growth

Industry leaders should adopt a multi-pronged strategy that aligns technology roadmaps with supply chain resilience and customer-centric commercialization. First, prioritize modular platform development that supports both centralized high-throughput needs and decentralized point-of-care deployment, enabling a single product family to serve multiple end-user requirements with shared consumables and validated workflows. This approach reduces complexity for customers and accelerates adoption across settings.

Second, diversify supply chains by qualifying alternative manufacturers for critical reagents and components, and by exploring regional manufacturing partnerships to mitigate tariff exposure and logistics risk. Coupling this with scenario-based procurement modeling will improve responsiveness to trade policy shifts. Third, expand offerings beyond hardware by embedding robust data analysis software, training and maintenance services that create recurring revenue and strengthen long-term customer relationships. Investing in intuitive user interfaces and integrated reporting will reduce the total cost of ownership for buyers.

Fourth, engage proactively with regulators and clinical stakeholders to streamline validation pathways and to demonstrate clinical utility through real-world evidence initiatives. Finally, cultivate strategic collaborations with academic and clinical partners to accelerate assay development for priority applications such as infectious disease surveillance, oncology biomarker testing and rare disease diagnostics, thereby enhancing competitive differentiation and adoption momentum.

Outlining a mixed-methods research approach combining expert interviews, technical review and scenario analysis to validate insights across the nucleic acid amplification testing value chain

The research methodology underpinning this analysis combined structured primary research, targeted secondary inquiry and rigorous validation to ensure relevance and accuracy. Primary research included in-depth interviews with clinical laboratory directors, hospital procurement officers, assay developers, and technology vendors to capture practical insights on adoption drivers, operational barriers and procurement dynamics. These qualitative inputs were supplemented by technical consultations with molecular biologists and bioinformatics specialists to assess assay performance trade-offs and integration challenges.

Secondary research involved a comprehensive review of peer-reviewed literature, regulatory guidance documents, patent filings, and publicly available product specifications to map technology capabilities and compliance requirements. Supply chain assessments incorporated trade data and supplier disclosures to evaluate manufacturing footprints and potential vulnerabilities. The analysis also applied scenario planning to test the sensitivity of commercialization strategies to variables such as tariff changes, regulatory timelines and shifts in clinical practice.

Findings were triangulated across sources and validated through follow-up discussions with subject matter experts. Care was taken to avoid proprietary vendor claims without corroboration, and methodological limitations related to rapidly changing policy environments and emerging technologies are noted to contextualize the conclusions and recommendations offered.

Summarizing the convergence of technological evolution, operational resilience and policy forces that will shape long-term adoption and value capture in nucleic acid amplification testing

In conclusion, nucleic acid amplification testing stands at a strategic inflection point where technological innovation, commercial strategy and policy dynamics intersect to determine future trajectories. The maturation of isothermal modalities alongside advanced PCR techniques, the proliferation of portable and benchtop platforms, and the integration of sophisticated data analysis tools collectively expand the range and settings for deployment. At the same time, evolving trade policies, regulatory expectations and regional manufacturing shifts require stakeholders to be deliberate in sourcing, validation and market entry decisions.

Organizations that successfully align product design with real-world workflow requirements, invest in supply chain resilience and prioritize service-oriented business models will be better equipped to capitalize on growing demand for rapid, accurate molecular diagnostics. Cross-sector collaboration among developers, clinicians and regulatory bodies will accelerate adoption and ensure that assays deliver meaningful clinical and public health value. By taking a disciplined, scenario-informed approach to strategy and execution, stakeholders can navigate near-term disruptions and position themselves for sustained leadership in the expanding NAAT ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nucleic Acid Amplification Testing Market, by Technology

  • 8.1. Isothermal Amplification
    • 8.1.1. Helicase Dependent Amplification
    • 8.1.2. Loop Mediated Amplification
    • 8.1.3. Nucleic Acid Sequence Based Amplification
    • 8.1.4. Strand Displacement Amplification
    • 8.1.5. Transcription Mediated Amplification
  • 8.2. Polymerase Chain Reaction
    • 8.2.1. Digital Polymerase Chain Reaction
    • 8.2.2. Real Time Polymerase Chain Reaction

9. Nucleic Acid Amplification Testing Market, by Product Type

  • 9.1. Instruments
    • 9.1.1. Benchtop Instruments
    • 9.1.2. Portable Instruments
  • 9.2. Reagents & Kits
    • 9.2.1. Buffers
    • 9.2.2. Enzymes
    • 9.2.3. Master Mixes
    • 9.2.4. Primers & Probes
  • 9.3. Software & Services
    • 9.3.1. Data Analysis Software
    • 9.3.2. Maintenance & Support
    • 9.3.3. Training & Consulting Services

10. Nucleic Acid Amplification Testing Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Hospitals
  • 10.3. Point Of Care Testing
  • 10.4. Research Institutes

11. Nucleic Acid Amplification Testing Market, by Application

  • 11.1. Companion Diagnostics
  • 11.2. Genetic Testing
    • 11.2.1. Carrier Screening
    • 11.2.2. Prenatal Genetic Testing
    • 11.2.3. Rare Disease Diagnostics
  • 11.3. Infectious Disease
    • 11.3.1. Bacterial Infectious Disease
    • 11.3.2. Parasitic Infectious Disease
    • 11.3.3. Viral Infectious Disease
  • 11.4. Oncology
    • 11.4.1. Biomarker Testing
    • 11.4.2. Minimal Residual Disease Detection
    • 11.4.3. Mutation Analysis

12. Nucleic Acid Amplification Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Nucleic Acid Amplification Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Nucleic Acid Amplification Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Nucleic Acid Amplification Testing Market

16. China Nucleic Acid Amplification Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton, Dickinson and Company
  • 17.7. BGI Genomics Co. Ltd.
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. bioMerieux SA
  • 17.10. Bruker Corporation
  • 17.11. Danaher Corporation
  • 17.12. Diasorin S.p.A.
  • 17.13. F. Hoffmann-La Roche AG
  • 17.14. Grifols, S.A.
  • 17.15. Hologic, Inc.
  • 17.16. Molbio Diagnostics Pvt. Ltd.
  • 17.17. Mylab Discovery Solutions
  • 17.18. Pfizer Inc
  • 17.19. QuidelOrtho Corporation
  • 17.20. Randox Laboratories Ltd
  • 17.21. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HELICASE DEPENDENT AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HELICASE DEPENDENT AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HELICASE DEPENDENT AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY LOOP MEDIATED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY LOOP MEDIATED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY LOOP MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY NUCLEIC ACID SEQUENCE BASED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STRAND DISPLACEMENT AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STRAND DISPLACEMENT AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY STRAND DISPLACEMENT AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIGITAL POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BENCHTOP INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PORTABLE INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PORTABLE INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PORTABLE INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BUFFERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BUFFERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BUFFERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MASTER MIXES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MASTER MIXES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MASTER MIXES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRIMERS & PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRIMERS & PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRIMERS & PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MAINTENANCE & SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TRAINING & CONSULTING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRENATAL GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRENATAL GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRENATAL GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RARE DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RARE DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY RARE DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PARASITIC INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PARASITIC INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PARASITIC INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY VIRAL INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY VIRAL INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY VIRAL INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BIOMARKER TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BIOMARKER TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY BIOMARKER TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MINIMAL RESIDUAL DISEASE DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MUTATION ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MUTATION ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY MUTATION ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 238. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 250. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 251. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 253. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 255. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 257. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 258. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 259. GCC NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS NUCLEIC ACID AMPLIFICATION TESTING MARKET SIZE, BY P